Early and Low Dose Deferasirox (3.5 mg/kg FCT) to Suppress NTBI and LPI as Early Intervention to Prevent Tissue Iron Overload in Lower Risk MDS

Myelodysplastic Syndromes Clinical Trial

Official title:

Early and Low Dose Deferasirox (3.5 mg/kg FCT) to Suppress NTBI and LPI as Early Intervention to Prevent Tissue Iron Overload in Lower Risk MDS

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT03920657
• Other study ID #: FISM_IRON-MDS
• Status: Terminated
• Phase: Phase 2
• Start date: October 4, 2019
• Est. completion date: April 22, 2022

Study information

• Verified date: March 2021
• Source: Fondazione Italiana Sindromi Mielodisplastiche-ETS
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The scientific rationale for this study is the evolving understanding that iron-induced tissue damage is not only a process of progressive bulking of organs through high-volumes iron deposition, but also a reactive iron species related "toxic" damage. Iron mediated damage can occur prior reaching high iron storage thresholds derived from thalassemia major setting, free toxic iron species being already present when transferrin saturation >60-70% (25); therefore a timely early adoption of iron chelation may be of benefit before overt iron overload is seen. Our hypothesis is that early and low dose DFX-FCT is better tolerated and is able to prevent iron accumulation and consequently tissue iron related damage, by consistently suppressing iron reactive oxygen species (NTBI and LPI). If this hypothesis is confirmed this approach could contribute to an improvement of clinical practice of patients managements. Additionally this approach might also be a contribute in preventing future iron overloaded related complication, in this already frail and co-treated patient population.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 11
• Est. completion date: April 22, 2022
• Est. primary completion date: October 6, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Diagnosis: Adult Myelodysplastic Syndrome (=18 years).
• Revised IPSS: very low. low - intermediate
• Having received 5-20 packed red blood cell units
• Serum ferritin =300 ng/ml
• Transferrin saturation = 60%
• Chelation naïve
• Capability to provide informed consent

Exclusion Criteria:

• Patients aged <18 years old
• Higher risk (revised IPSS) MDS (Intermediate 2, high)
• Cumulative transfusion story of > 20 packed red cell units
• Creatinine Clearance (CrCL): <60 ml/min. Patients with CrCl of 40-60ml/min will be included only individually if no other renal risk factors are present.
• Serum creatinine >2 x ULN at screening. If borderline serum creatinine will be measured within 7-10 days and the mean value will be used for eligibility criteria.
• Significant proteinuria as indicated by a urinary protein/creatinine ratio > 0.5 mg/mg in a non-first void urine sample (or alternatively in two of three samples obtained for screening).
• ECOG performance status >2.
• Left ventricular ejection fraction < 50% by echocardiography
• A history of repeated hospitalization for congestive heart failure.
• Systemic diseases that would prevent study treatment (e.g. uncontrolled hypertension, cardiovascular, renal, hepatic, metabolic, etc.)
• Clinical or laboratory evidence of chronic Hepatitis B or Hepatitis C (definition of chronic hepatitis follows EASL 2017 criteria).
• History of HIV positive test result (ELISA or Western blot).
• Treatment with systemic investigational drug within 4 weeks or topical investigational drug within 7 days of study start.
• ALT or AST over 3 times superior to ULN at screening.
• ANC < 500/ microL
• Platelets transfusion dependency
• Total bilirubin over 1.5 times superior to ULN at screening (patients with Gilbert syndrome are allowed to enter the study)
• Diagnosis of Child score C liver cirrhosis.
• Patients participating in another clinical trial other than an observational registry study.
• Patients with a history of another malignancy within the past 3 years, with the exception of basal skin carcinoma or cervical carcinoma in situ or completely resected colonic polyps carcinoma in situ.
• History of non-compliance to medical regimens, or patients who are considered potentially unreliable and/or not cooperative.
• Presence of a surgical or medical condition which might significantly alter the absorption, distribution, metabolism or excretion of study drug.
• Pregnant, intending-to-become pregnant, or breast-feeding patients.
• Women of potential maternity age who do not agree to practice effective contraceptive methods fo the entire study duration.
• History of drug or alcohol abuse within the 12 months prior to enrollment.
• Hypersensitivity to the active substance or to any of the excipients.
• Inability to provide a valid informed consent

Related Conditions & MeSH terms

• Iron Overload
• Myelodysplastic Syndromes

Intervention

Drug:
• Deferasirox
Fixed dose of 3.5 mg/kg/day of DFX FCT

Locations

Country	Name	City	State
Italy	Ematologia - Spedali Civili	Brescia
Italy	Ospedale Businco	Cagliari
Italy	S.O.D. Ematologia Policlino Careggi	Firenze	FI
Italy	Ospedale San Martino	Genova
Italy	Ospedale Niguarda	Milano
Italy	Medicina Interna II Divisione di Ematologia, Ospedale S. Luigi Gonzaga	Orbassano	TO
Italy	Azienda Ospedaliera di Padova	Padova
Italy	AO Bianchi Melacrino Morelli	Reggio Calabria
Italy	Ospedale S. Eugenio	Roma
Italy	Istituto clinico Humanitas	Rozzano (MI)

Sponsors (1)

Lead Sponsor	Collaborator
Fondazione Italiana Sindromi Mielodisplastiche-ETS

Country where clinical trial is conducted

Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change of hepatic iron	Change of hepatic iron from the baseline according to baseline hepatic iron level: For patients with baseline LIC =5 mg/g dry weight (dw) ± 1.5 mg/g dw. For patients with baseline LIC >5 mg/g dw ±20%	1 year
Secondary	Definition of iron overload	The baseline iron status of MDS patients at the beginning of their transfusion story is today unknown. This study is the first unbiased and direct measurement of iron stress and oxidative stress in MDS patients at the beginning of the transfusion story.; Baseline iron status will be described by classical iron markers: serum ferritin (ng/ml), transferritin saturation (%), liver and pancreas iron concentration by MRI (mg/g dry weight). Total body iron stores will be calculated (mg/kg) with the published formula (N Engl J Med 2000; 343:327-331).; Tissue reactive oxygen species will be measured in the patient's plasma as follows: non-transferrin bound iron= micromoles/L, Labile Plasma Iron= micromoles/L. Oxidative stress will be measured by Malonildialdehyde (MDA). Levels in plasmas= micromoles/L.	1 year
Secondary	Efficacy of treatment	Absolute change in hepatic iron concentration EOS versus baseline.	1 year
Secondary	Evolution of iron overload serologic markers	Absolute and relative changes in serum ferritin and transferrin saturation from baseline to every visit during the whole treatment period	1 year
Secondary	Evolution of toxic serum iron forms	Presence and quantitative evolution of toxic serum iron forms (iron tissue reactive species) under low dose DFX therapy	1 year
Secondary	Relationship between NTBI and LPI with serum ferritin and liver and pancreas iron overload	Prevention of iron overload will be studied by the difference iron parameters end of therapy - baseline by liver iron concentration (mg/g dry weight), pancreas iron concentration (mg/g dry weight), total body iron stores (mg/kg) calculated the N Engl J med 2000 343:327-331 formula = liver iron concentration x 10.6.; Serum ferritin = ng/ml.; Relationship between suppression of tissue iron species and prevention of iron accumulation (observational study) will be measured by the: NTBI/LPI values (micromoles/L), Differences end of study - baseline quantitative parameters of iron loading (liver and pancreas iron concentration and total body iron stores).	1 year
Secondary	Overall safety of deferasirox	Evaluate the overall safety of deferasirox FCT formulation in patients with lower risk MDS at the beginning of their transfusional history	1 year
Secondary	Leukemic transformation	Leukemic transformation (progression to leukemia or higher rIPSS scores)	1 year
Secondary	Hemopoietic response	Percentage of patients with hematologic improvements in term of erythroid response following IWG 2006 criteria.	1 year
Secondary	Costs analysis	Treatment cost will be compared with standard approach cost (14 mg/kg/day. DFX-FCT after 20 units of packed red cells units and serum ferritin> 1000 ng/ml over one year of treatment). For comparison literature and matched FISM registry data will be used. Unit of measurement will be 2019 USD and Euros.	1 year
Secondary	Study of biological cellular damage	Biological cellular damage will be measured by presence and level of oxidative stress determined at baseline, during and at end of study and compared with ongoing treatment by: Malonildialdehyde (MDA) plasma levels (micromoles/L).	1 year